AGP

Artia Global Partners Portfolio holdings

AUM $389M
1-Year Est. Return 34.68%
This Quarter Est. Return
1 Year Est. Return
+34.68%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$389M
AUM Growth
+$47.8M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
44
New
Increased
Reduced
Closed

Top Buys

1
+$43.7M
2
+$36.9M
3
+$36.5M
4
TRVI icon
Trevi Therapeutics
TRVI
+$7.18M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.6M

Top Sells

1
+$50M
2
+$29M
3
+$17.2M
4
ACLX icon
Arcellx
ACLX
+$15M
5
MRUS icon
Merus
MRUS
+$6.73M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$3.32B
$1.25M 0.3%
40,000
BHVN icon
27
Biohaven
BHVN
$1.86B
$1.13M 0.27%
+80,000
RNA icon
28
Avidity Biosciences
RNA
$7.15B
$983K 0.24%
+34,600
KNSA icon
29
Kiniksa Pharmaceuticals
KNSA
$2.88B
$808K 0.19%
+29,200
MLYS icon
30
Mineralys Therapeutics
MLYS
$3.43B
$556K 0.13%
+41,100
NAMS icon
31
NewAmsterdam Pharma
NAMS
$4.24B
$495K 0.12%
+27,319
JANX icon
32
Janux Therapeutics
JANX
$1.62B
$462K 0.11%
20,000
-18,100
TVTX icon
33
Travere Therapeutics
TVTX
$2.49B
$457K 0.11%
30,900
ACLX icon
34
Arcellx
ACLX
$4.81B
– –
-229,085
CNTA
35
Centessa Pharmaceuticals
CNTA
$3.05B
– –
-35,226
ISRG icon
36
Intuitive Surgical
ISRG
$166B
– –
-3,500
NBIX icon
37
Neurocrine Biosciences
NBIX
$14B
– –
-14,700
NUVL icon
38
Nuvalent
NUVL
$7.01B
– –
-90,745
RYTM icon
39
Rhythm Pharmaceuticals
RYTM
$7.46B
– –
-50,000
UGL icon
40
ProShares Ultra Gold
UGL
$924M
– –
0
VRDN icon
41
Viridian Therapeutics
VRDN
$1.96B
– –
-160,000
XBI icon
42
SPDR S&P Biotech ETF
XBI
$6.34B
– –
0
ORKA
43
Oruka Therapeutics
ORKA
$1.33B
– –
-7,380
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-219,719
1
2